Choline epalrestat - NeuroMax

Drug Profile

Choline epalrestat - NeuroMax

Alternative Names: BNV-222; Choline cocrystal of epalrestat - Bionevia Pharmaceuticals; Choline diepalrestat; Diepalrestat; NM-IA-001

Latest Information Update: 18 May 2016

Price : $50

At a glance

  • Originator Bionevia Pharmaceuticals
  • Developer NeuroMax
  • Class Antihyperglycaemics; Small molecules; Thiazoles; Thiazolidines
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Diabetic neuropathies

Most Recent Events

  • 16 May 2016 BioNevia and NeuroMax completes enrolment in a phase II/III trial for Diabetic Neuropathy in Russia
  • 01 Nov 2014 Phase-II/III clinical trials in Diabetic neuropathies in Russia (PO) (NCT02332005)
  • 18 Jul 2013 NeuroMax initiates enrolment in a phase Ib trial for Diabetic neuropathies in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top